Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.

Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review

“…Of the 47 studies which appeared to be eligible after the initial screening, a full text search was performed. A total of 21 studies were removed after the full text search; thus, 26 studies were included in the final analysis: four Phase III trials [16][17][18][19], 16 Phase II trials [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35], one Phase I study [36] and five retrospective studies (tables 1-3) [37][38][39][40][41]. In total, 11 studies deal with second-line setting while 15 studies deal with third or fourth lines.…”